{"id":42221,"date":"2025-09-25T12:01:47","date_gmt":"2025-09-25T04:01:47","guid":{"rendered":"https:\/\/flcube.com\/?p=42221"},"modified":"2025-09-25T12:01:48","modified_gmt":"2025-09-25T04:01:48","slug":"hengrui-pharma-glenmark-partner-on-trastuzumab-rezecan-adc-for-her2%e2%80%91positive-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42221","title":{"rendered":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>)<\/strong> announced an exclusive licensing agreement with <strong>Glenmark Specialty S.A. (GSSA)<\/strong>, a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize <strong>trastuzumab\u202frezetan<\/strong> (SHR\u2011A1811) outside China.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-snapshot\">Product Snapshot<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trastuzumab\u202frezetan<\/strong> is a next\u2011generation antibody\u2011drug conjugate (ADC) that couples the HER2\u2011specific monoclonal antibody trastuzumab to a potent anti\u2011cancer payload via a cleavable linker.<\/li>\n\n\n\n<li>The ADC was granted approval in China in May\u202f2025 for adult patients with <strong>unresectable, locally advanced or metastatic non\u2011small\u2011cell lung cancer (NSCLC)<\/strong> harboring <strong>HER2 (ERBB2) activating mutations<\/strong> who have received at least one prior systemic therapy.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-licensing-deal-highlights\">Licensing Deal Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Territory<\/strong><\/td><td>Glenmark receives exclusive rights to develop and commercialize the drug <strong>outside China, the U.S., Canada, Europe, Japan, Russia, and 13 Central Asian republics<\/strong>.<\/td><\/tr><tr><td><strong>Financials<\/strong><\/td><td>Hengrui Pharma will receive an <strong>upfront payment of USD\u202f18\u202fmillion<\/strong>, with <strong>milestone payments up to USD\u202f1.093\u202fbillion<\/strong> tied to regulatory approvals and sales, plus <strong>sales\u2011royalties<\/strong>.<\/td><\/tr><tr><td><strong>Strategic Fit<\/strong><\/td><td>The partnership leverages Glenmark\u2019s global commercial network and Hengrui\u2019s proven pipeline in oncology, positioning the ADC for rapid entry into key international markets.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-competitive-landscape\">Market &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The global HER2\u2011positive NSCLC market is projected to reach <strong>$4\u202fbillion<\/strong> by 2030, driven by expanding indications for HER2\u2011targeted therapies.<\/li>\n\n\n\n<li>Trastuzumab\u202frezetan\u2019s oral\u2011ready ADC platform differentiates it from existing antibody\u2011based therapies such as <strong>pertuzumab<\/strong> and <strong>lapatinib<\/strong> by delivering cytotoxic payloads directly to tumor cells while sparing healthy tissue.<\/li>\n\n\n\n<li>Glenmark\u2019s prior success with ADCs in hematology and solid tumors (e.g., <strong>belantamab mafodotin<\/strong>) positions it well to accelerate the commercial rollout of SHR\u2011A1811.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hengrui Pharma anticipates that the partnership will <strong>shorten time\u2011to\u2011market<\/strong> for trastuzumab\u202frezetan in regions where regulatory pathways are more streamlined.<\/li>\n\n\n\n<li>Glenmark plans to initiate <strong>phase\u2011III global trials<\/strong> in late 2026, aiming for regulatory submissions in the U.S. and EU by 2028.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,2586,4228,852],"class_list":["post-42221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42221\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42221\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-25T04:01:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-25T04:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer\",\"datePublished\":\"2025-09-25T04:01:47+00:00\",\"dateModified\":\"2025-09-25T04:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2501.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42221#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42221\",\"name\":\"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2501.webp\",\"datePublished\":\"2025-09-25T04:01:47+00:00\",\"dateModified\":\"2025-09-25T04:01:48+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42221\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Pharma & Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42221#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42221","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer","og_description":"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.","og_url":"https:\/\/flcube.com\/?p=42221","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-25T04:01:47+00:00","article_modified_time":"2025-09-25T04:01:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42221#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42221"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer","datePublished":"2025-09-25T04:01:47+00:00","dateModified":"2025-09-25T04:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42221"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42221#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","keywords":["ADC \/ XDC","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42221#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42221","url":"https:\/\/flcube.com\/?p=42221","name":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42221#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42221#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","datePublished":"2025-09-25T04:01:47+00:00","dateModified":"2025-09-25T04:01:48+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark Specialty S.A. (GSSA), a wholly\u2011owned subsidiary of Glenmark\u202fPharmaceuticals, to develop and commercialize trastuzumab\u202frezetan (SHR\u2011A1811) outside China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42221#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42221"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42221#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","width":1080,"height":608,"caption":"Hengrui Pharma & Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42221#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma &amp; Glenmark Partner on Trastuzumab\u202fRezecan ADC for HER2\u2011Positive Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42221"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42221\/revisions"}],"predecessor-version":[{"id":42223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42221\/revisions\/42223"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42222"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}